Skip to main content
Premium Trial:

Request an Annual Quote

Strasbourg U Inks Deal to Process CareDx AlloMap Tests in Europe

NEW YORK (GenomeWeb) – CareDx today announced that its European distributor of AlloMap tests, Diaxonhit, has signed a service sub-licensing agreement with the Strasbourg University Hospitals to perform all AlloMap testing at a dedicated facility in Strasbourg, France.

Diaxonhit is the exclusive distributor of AlloMap in Europe. The blood-based molecular diagnostic test allows clinicians to monitor heart transplant recipients for acute cellular rejection.

Patient blood samples will be collected in heart transplant centers around Europe and shipped to the dedicated facility at the university's Central Laboratory of Immunology in Strasbourg, where all testing will be performed. Test results will be sent back to clinicians directly from the laboratory.

Selecting the laboratory was a "key milestone" in implementing AlloMap in Europe, Loïc Maurel, president of Diaxonhit's management board, said in a statement. "We were impressed by the enthusiasm and dedication of the [Strasbourg University Hospitals] staff, and feel that AlloMap testing will be performed by the best possible team."

The location in Strasbourg is advantageous, Diaxonhit said in a statement, because it is centrally positioned between southern and northern Europe, on the French-German border, allowing for quick transportation of samples from anywhere on the continent.

Financial details of the arrangement were not disclosed.